LEADER 05473nam 2200673 a 450 001 9910451821703321 005 20200520144314.0 010 $a1-280-66895-4 010 $a9786613645883 010 $a1-84816-450-5 035 $a(CKB)2550000000101716 035 $a(EBL)919104 035 $a(OCoLC)794328399 035 $a(SSID)ssj0000657469 035 $a(PQKBManifestationID)12277381 035 $a(PQKBTitleCode)TC0000657469 035 $a(PQKBWorkID)10674717 035 $a(PQKB)10002415 035 $a(MiAaPQ)EBC919104 035 $a(WSP)00002660 035 $a(Au-PeEL)EBL919104 035 $a(CaPaEBR)ebr10563562 035 $a(CaONFJC)MIL364588 035 $a(EXLCZ)992550000000101716 100 $a20120608d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMolecular exploitation of apoptosis pathways in prostate cancer$b[electronic resource] /$fNatasha Kyprianou 210 $aLondon $cImperial College Press$d2012 215 $a1 online resource (230 p.) 225 1 $aMolecular medicine and medicinal chemistry ;$vv. 5 300 $aDescription based upon print version of record. 311 $a1-84816-449-1 320 $aIncludes bibliographical references and index. 327 $aContents; Preface; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor 327 $a3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures 327 $a4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-?: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin 327 $a5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-? Signaling 327 $a7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention 327 $a9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 330 $aThis book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis 410 0$aMolecular medicine and medicinal chemistry ;$vv. 5. 606 $aApoptosis 606 $aProstate$xCancer$xTreatment 608 $aElectronic books. 615 0$aApoptosis. 615 0$aProstate$xCancer$xTreatment. 676 $a616.99463 700 $aKyprianou$b Natasha$0885817 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451821703321 996 $aMolecular exploitation of apoptosis pathways in prostate cancer$91977920 997 $aUNINA LEADER 02962nam 2200613 a 450 001 9910779861903321 005 20230803215957.0 010 $a0-19-936112-6 010 $a0-19-998872-2 035 $a(CKB)2550000001100340 035 $a(EBL)1318297 035 $a(SSID)ssj0000949693 035 $a(PQKBManifestationID)12466999 035 $a(PQKBTitleCode)TC0000949693 035 $a(PQKBWorkID)11004666 035 $a(PQKB)10599088 035 $a(MiAaPQ)EBC1318297 035 $a(Au-PeEL)EBL1318297 035 $a(CaPaEBR)ebr10733607 035 $a(CaONFJC)MIL504766 035 $a(OCoLC)852899172 035 $a(EXLCZ)992550000001100340 100 $a20130501d2014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAmerican psychosis$b[electronic resource] $ehow the federal government destroyed the mental illness treatment system /$fE. Fuller Torrey 210 $aOxford $cOxford University Press$d2014 215 $a1 online resource (219 p.) 300 $aDescription based upon print version of record. 311 $a0-19-998871-4 311 $a1-299-73515-0 320 $aIncludes bibliographical references and index. 327 $aJoe Kennedy : a man with problems -- Robert Felix : a man with plans -- The birth of the federal mental health program: 1960-1963 -- The short, unhappy life of the federal mental health program: 1964-1970 -- The death of the federal mental health program: 1971-1980 -- The perfect storm: 1981-1999 -- Dimensions of the current disaster: 2000-2013 -- Solutions : what have we learned and what should we do?. 330 $aIn 1963, President John F. Kennedy delivered an historic speech on mental illness and retardation. He described sweeping new programs to replace ""the shabby treatment of the many millions of the mentally disabled in custodial institutions"" with treatment in community mental health centers. This movement, later referred to as ""deinstitutionalization,"" continues to impact mental health care. Though he never publicly acknowledged it, the program was a tribute to Kennedy's sister Rosemary, who was born mildly retarded and developed a schizophrenia-like illness. Terrified she'd become pregnant, 606 $aMentally ill$xCare$zUnited States$xHistory 606 $aMentally ill$xServices for$zUnited States 606 $aMental health policy$zUnited States 606 $aMental health services$zUnited States$xEvaluation 615 0$aMentally ill$xCare$xHistory. 615 0$aMentally ill$xServices for 615 0$aMental health policy 615 0$aMental health services$xEvaluation. 676 $a362.1968900973 700 $aTorrey$b E. Fuller$g(Edwin Fuller),$f1937-$01116018 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910779861903321 996 $aAmerican psychosis$93795226 997 $aUNINA